Dr. Jonasson is a co-founder and Managing Partner at Phoenix Venture Partners. He has founded multiple biotechnology companies and currently serves on the board of several biotech companies. Dr. Jonasson is an alumni of the Kauffman Fellowship program and has led investments in advanced materials and life science startups over the past 25 years.

Dr. Lawlis is a renowned bioprocessing scientist and executive with over 36 years of experience in the biotech industry. He started his career at Genentech, working there from 1981-1996, ultimately serving as Vice President of Process Engineering. He has since founded multiple companies, acting as CEO for Itero Biopharmaceuticals, Aradigm, FUJIFILM Diosynth, and Covance. He currently holds board appointments at BioMarin, Coherus, Geron, Sutro, and Reform Biologics, and is an advisor to Phoenix Venture Partners.

Sean is a biotech innovator and entrepreneur who defies established approaches to biomanufacturing and drug development. While earning his degrees in biochemistry and molecular biology, McClain began developing a revolutionary new protein expression platform. McClain has since invented several patented technologies and under his leadership AbSci has grown into a global leader in the biomanufacturing industry.

Dr. Gold is a widely recognized leader in bioprocessing with expertise in upstream, downstream, formulation, and analytical development. He has over 30 years of industry experience as both a scientist and executive, including Genentech, Human Genome Sciences, Covance, and Sutro Biopharma, where he acted as CEO. Dr. Gold is currently Vice President of Process Sciences at BioMarin where he oversees all bioprocessing activities.

Dr. Mahler joined AGC Biologics (previously CMC Biologics) in 2008 as President. In 2010, he was named global Chief Operations Officer and in January, 2016 he became Chief Executive Officer. Prior to joining CMC Biologics, he worked for 15 years at Bayer in the United States, Europe and Latin America, serving in various manufacturing and general management positions. Dr. Mahler received his Ph.D. in Biochemistry from the University of Buenos Aires and holds a Master’s of Business Administration from the University UNED of Madrid and an Executive Certification in Management from MIT Sloan.

Sean is a biotech innovator and entrepreneur who defies established approaches to biomanufacturing and drug development. While earning his degrees in biochemistry and molecular biology, McClain began developing a revolutionary new protein expression platform. McClain has since invented several patented technologies and under his leadership AbSci has grown into a global leader in the biomanufacturing industry.

Suzanne has a Ph.D. in Genetics from the University of Wisconsin and worked as a patent attorney for Wyeth, Immunex, and Amgen.  She has directed AbSci’s patent portfolio since 2012, and now serves as Chief Intellectual Property Officer.

Shelley has a Bachelors of Science in Accounting from the University of Kentucky. For nearly 20 years, she has worked for both established and startup companies across a variety of industries in the role of public accountant, Controller, and CFO. She has served as Chief Financial Officer for AbSci since March 2016.

The face of AbSci. Always eager to welcome guests. She lives on the finest doggy treats and lunchtime spills. Her four years’ experience as a loyal friend is always helpful. But what she brings most to the team is an extensive understanding of chew toys and Frisbee games.

Dan has served in senior roles as general counsel for multiple large biotech companies during his 25 year career, including Genentech, Abgenix (now Amgen), Roche, and Chiron. He brings extensive experience integrating science, business development, and legal disciplines which he leverages to manage AbSci’s licensing, contracts, and patent strategy.

Dr. Lawlis is a renowned bioprocessing scientist and executive with over 36 years of experience in the biotech industry. He started his career at Genentech, working there from 1981-1996, ultimately serving as Vice President of Process Engineering. He has since founded multiple companies, acting as CEO for Itero Biopharmaceuticals, Aradigm, FUJIFILM Diosynth, and Covance. He currently holds board appointments at BioMarin, Coherus, Geron, Sutro, and Reform Biologics, and is an advisor to Phoenix Venture Partners.

Dr. Bennett is a renowned specialist in downstream process development and regulatory affairs. He spent 18 years at Genentech in various roles, rising to Sr. Director of Regulatory Policy and leading the Genentech Biosimilars working group. Since Genentech, he has held various Senior roles in the biotech industry. Dr. Bennett’s work on blood platelets, neurobiology, human growth hormone and tissue-type plasminogen activator, have fueled medicines that have saved thousands of lives.

Dr. Gold is a widely recognized leader in bioprocessing with expertise in upstream, downstream, formulation, and analytical development. He has over 30 years of industry experience as both a scientist and executive, including Genentech, Human Genome Sciences, Covance, and Sutro Biopharma, where he acted as CEO. Dr. Gold is currently Vice President of Process Sciences at BioMarin where he oversees all bioprocessing activities.

Dr. Larimore has over 30 years of experience in development and manufacturing of recombinant proteins. During his tenure at Eli Lilly as a senior scientific leader, he led manufacturing support for six major biotechnology products in the marketplace, including Xigris®, Humulin®, Humalog®, Humatrope®, Forteo® and Recombinant Human Glucagon. He was influential in developing some of the original biologic manufacturing processes that resulted in scale-up of insulin production.

Dr. Herman is a pioneer in protein analysis and characterization. He has been influential in establishing guidelines and concepts that are currently used biologics characterization. During his 30-year career, Dr. Herman has worked at numerous biotech companies, including Genentech, Merck, and Amgen, and is currently CSO at Coherus Bioscience.

Dr. Jones is a recognized expert in analytical biotechnology. Trained as a protein biochemist/biophysicist, he spent 24 years at Genentech in various positions with expertise in product development, protein analysis and formulation, and glycobiology. He was founding director of the analytical development dept and was a Staff Scientist for 18 years. Since Genentech, he has worked in an advisory capacity to a range of other biotech companies.